CompletedPhase 1

Targeting Platelet-Leukocyte Aggregates in Pneumonia With Ticagrelor

United States60 participantsStarted 2013-06

Plain-language summary

The hypothesis to be tested is that ticagrelor (Brilinta™) will reduce platelet activation and markers of inflammation in patients with pneumonia.

Who can participate

Age range

18 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

. Cough
. Fever: axillary temperature \>37.5ºC or tympanic temperature \>38.5ºC
. Hypothermia: axillary temperature \<34ºC or tympanic temperature \<35ºC.
. Purulent sputum production or respiratory secretion.
. Total peripheral white blood cell (WBC) count \>10,000/mm3; or \>15% band forms, regardless of total peripheral white count; or leucopenia with total WBC \< 4500/mm
. Auscultatory findings on pulmonary examination of rales and/or evidence of pulmonary consolidation (dullness on percussion, bronchial breath sounds, or egophony)
. Hypoxemia - defined as partial O2 pressure \<60mmHg while the patient was breathing normal air or a decrease in the partial O2 pressure of \>= 25% from an initial range.

Exclusion criteria

. Contraindication to ticagrelor (hypersensitivity or reaction to ticagrelor or another P2Y12 antagonist)
. Active bleeding or major bleeding history (e.g. intracranial bleeding)
. Clinically important anemia or thrombocytopenia (platelet count \<30)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Platelet-Leukocyte Aggregates

Timeframe: 30 day

Trial details

NCT IDNCT01883869

SponsorUniversity of Kentucky

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Pneumonia trials